Plasma basic fibroblast growth factor levels in colorectal cancer: A clinically useful assay? (original) (raw)

Abstract

Angiogenic cytokines in the plasma and serum of cancer patients may serve as `surrogate' markers of tumour neoangiogenesis. Serum VEGF correlates with disease stage in colorectal cancer (CRC), but the role of bFGF in CRC is uncertain. This study aimed to assess plasma bFGF levels in CRC patients before treatment, during chemoradiotherapy and at one-year follow-up. Plasma samples were taken from 124 CRC patients, 26 polyp patients and 55 controls, and bFGF levels were measured by ELISA. 19 patients underwent pre-operative chemoradiotherapy. One-year follow-up samples were available from 48 disease-free patients and 18 patients with progressive disease. There were no detectable differences between plasma bFGF levels in polyp, Dukes' A or B patients (4.55, 5.77, 4.25 pg/ml, respectively), but there was a significant increase in metastatic CRC patients [Dukes' C and D (7.42 and 6.6 pg/ml; _P_=0.004 and 0.048, respectively)], relative to median control levels of 4.14 pg/ml. At follow-up, there was a significant fall in plasma bFGF levels in disease-free patients (pre-op 6.09 and follow-up 3.45 pg/ml, _P_=0.0004), but a non-significant rise in 18 patients with progressive disease (pre-treatment 5.90 and follow-up 9.99 pg/ml, _P_=0.33). Pre-treatment plasma bFGF in patients receiving chemo-radiotherapy was similar in those with responsive and non-responsive tumours. There were no detectable changes in plasma bFGF through the adenoma-carcinoma sequence or patient groups with non-metastatic cancers. Elevated plasma bFGF was, however, associated with metastatic spread. The significant fall in bFGF in disease-free patients following therapy suggests that bFGF may be useful in clinical practice.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.
    PubMed CAS Google Scholar
  2. George ML, Eccles SA, Tutton MG et al. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6: 3147–52.
    PubMed CAS Google Scholar
  3. Kumar H, Heer K, Lee PW et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279–85.
    PubMed CAS Google Scholar
  4. Asahara T, Bauters C, Zheng LP et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92: II365–71.
    PubMed CAS Google Scholar
  5. Dirix LY, Vermeulen PB, Hubens G et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996; 7: 843–8.
    PubMed CAS Google Scholar
  6. Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 2000; 85: 40–5.
    Article PubMed CAS Google Scholar
  7. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356–61.
    PubMed CAS Google Scholar
  8. Salgado R, Vermeulen PB, Benoy I et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80: 892–7.
    Article PubMed CAS Google Scholar
  9. Dirix LY, Vermeulen PB, Pawinski A et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238–43.
    PubMed CAS Google Scholar
  10. George ML, Dzik-Jurasz AS, Padhani AR et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001; 88: 1628–36.
    Article PubMed CAS Google Scholar
  11. Meyer GE, Yu E, Siegal JA et al. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995; 76: 2304–11.
    Article PubMed CAS Google Scholar
  12. Brattstrom D, Bergqvist M, Larsson A et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998; 18: 1123–7.
    PubMed CAS Google Scholar
  13. Sliutz G, Tempfer C, Obermair A et al. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 1995; 15: 2675–7.
    PubMed CAS Google Scholar
  14. Pichon MF, Moulin G, Pallud C et al. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res 2000; 20: 1189–94.
    PubMed CAS Google Scholar
  15. Colomer R, Aparicio J, Montero S et al. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 1997; 76: 1215–20.
    PubMed CAS Google Scholar
  16. Dosquet C, Coudert MC, Lepage E et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3: 2451–8.
    PubMed CAS Google Scholar
  17. Landriscina M, Cassano A, Ratto C et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78: 765–70.
    PubMed CAS Google Scholar
  18. Ueno K, Inoue Y, Kawaguchi T et al. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001; 31: 213–9.
    Article PubMed CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Colorectal Unit, Mayday University Hospital, Thornton Heath, Croydon, UK
    M.L. George, M.G. Tutton, A.M. Abulafi & R.I. Swift
  2. CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK
    M.L. George, M.G. Tutton & S.A. Eccles

Authors

  1. M.L. George
    You can also search for this author inPubMed Google Scholar
  2. M.G. Tutton
    You can also search for this author inPubMed Google Scholar
  3. A.M. Abulafi
    You can also search for this author inPubMed Google Scholar
  4. S.A. Eccles
    You can also search for this author inPubMed Google Scholar
  5. R.I. Swift
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toM.L. George.

Rights and permissions

About this article

Cite this article

George, M., Tutton, M., Abulafi, A. et al. Plasma basic fibroblast growth factor levels in colorectal cancer: A clinically useful assay?.Clin Exp Metastasis 19, 735–738 (2002). https://doi.org/10.1023/A:1021322201816

Download citation